Epidemiologic studies have consistently found that self-reported allergies are associated with reduced risk of pancreatic cancer. Our aim was to prospectively assess the relationship between serum immunoglobulin E (IgE), a marker of allergy, and risk. This nested case–control study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) included subjects enrolled in 1994 to 2001 and followed through 2010. There were 283 cases of pancreatic cancer and 544 controls matched on age, gender, race, and calendar date of blood draw. Using the ImmunoCAP system, we measured total IgE (normal, borderline, elevated), IgE to respiratory allergens, and IgE to food allergens (negative or positive) in serum collected at baseline. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. We assessed interactions with age, gender, smoking, body mass index, and time between randomization and case diagnosis. Overall, there was no association between the IgE measures and risk. We found a statistically significant interaction by baseline age: in those aged ≥65 years, elevated risks were observed for borderline total IgE (OR, 1.43; 95% CI, 0.88–2.32) and elevated total IgE (OR, 1.98; 95% CI, 1.16–3.37) and positive IgE to food allergens (OR, 2.83; 95% CI, 1.29–6.20); among participants <65 years, ORs were <1. Other interactions were not statistically significant. The reduced risk of pancreatic cancer associated with self-reported allergies is not reflected in serum IgE. Cancer Epidemiol Biomarkers Prev; 23(7); 1414–20. ©2014 AACR.

Pancreatic cancer is a deadly disease, with 5-year survival only 6% (1). A consistent finding in epidemiologic studies is reduced risk associated with self-reported allergies (2–5). Very little is known about the biologic basis of this association, which is found in other cancers as well (5). For pancreatic cancer, evidence of reduced risk is most consistent for respiratory allergies, whereas asthma is not associated with risk. Although few studies have investigated food allergies, there is little evidence of an association with risk (3).

Individuals with allergies are characterized by high levels of serum immunoglobulin E (IgE), both total IgE and allergen-specific IgE. We hypothesized that measures of total IgE and specific IgE to respiratory allergens would be inversely associated with risk of pancreatic cancer; we did not have a specific hypothesis about IgE to food allergens. Tests of total and specific IgE may point toward a functional allergy pathway that cannot be inferred from self-reported allergy. We tested this hypothesis in the National Cancer Institute's prospective Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Study population

We used a nested case–control design within PLCO, a randomized trial investigating the effects of screening for prostate, lung, colorectal, and ovarian cancers (6). From 1994 to 2001, >150,000 men and women ages 55 to 74 years at entry were randomized at 10 screening centers to receive screening or usual care. Participants were eligible if they were not currently undergoing treatment for any cancer (except nonmelanoma skin cancer) and had not been diagnosed with one of the cancers under study. Participants completed baseline questionnaires on background characteristics and provided a blood sample. Questions on allergies were not included.

Cases had confirmed incident primary pancreatic adenocarcinomas diagnosed from 1994 to 2010 (ICDO3 codes C250–C259, excluding histology codes for endocrine neoplasms). They were identified by an annual mail survey to participants or next of kin and search of cancer registries and death certificates.

A total of 295 pancreatic cancer cases were identified. Controls unaffected by pancreatic cancer were alive in the year of the matched cases' diagnosis and were matched to each case in a 2:1 ratio on age at randomization (<60, 60–64, 65–69, ≥70), year of birth (in 5-year groups from 1920–1924 to 1945–1949), gender, race, and calendar date of blood draw (in 2-month groups, beginning with January/February). Twelve cases and 26 controls were excluded from analysis because they had missing information on all 3 IgE measures; in addition, 20 more controls were excluded because their matched cases were excluded, resulting in a total of 283 cases and 544 matched controls.

The PLCO study was approved by the institutional review boards of the screening centers and the National Cancer Institute. This analysis was reviewed by the institutional review board at Memorial Sloan Kettering Cancer Center.

Measurement of total and allergen-specific IgE

Blood samples were collected at study entry, processed within 2 hours, and stored at −70°C. IgE measures were undertaken in the Laboratory for Molecular Epidemiology at the University of California San Francisco using the ImmunoCAP Fluorescent Enzyme Immunoassay system (Thermo Fisher Scientific; ref. 7). ImmunoCAP is a fluorescent assay in which the solid phase is a flexible, hydrophobic cellulose polymer to which allergen has been covalently linked. The system has a very high binding capacity and minimal nonspecific binding. For allergen-specific IgE, ImmunoCAP's Phadiatop combines specific respiratory allergens that identify about 97% of individuals with respiratory allergies in the United States; information on the specific allergens included is not provided. The food panel includes peanuts, tree nuts, shellfish, milk, egg, and codfish. Laboratory technicians were blinded to case–control status. We categorized the IgE measures using standard cut points: for total IgE, normal (<25 kU/L), borderline (25–100 kU/L), and elevated (>100 kU/L); for IgE for respiratory allergens and food allergens, negative (<0.35 kU/L) or positive (i.e., detectable; ≥0.35 kU/L). For total IgE, we additionally analyzed risk for those with very elevated levels (>310 kU/L, the 90th percentile). In the UCSF laboratory, the range of coefficients of variation percent for measures of total IgE is 2.0 to 2.8 within assays and 5.3 to 9.1 between. For specific IgE, the corresponding ranges are 5 to 6 and 10 to 11.

Statistical analysis

We prepared descriptive statistics for cases and controls of demographic characteristics (education, marital status, occupation), design factors (study center and season of blood draw), and risk factors for pancreatic cancer [cigarette smoking, body mass index (BMI, weight (k)/height (m2))], diabetes, alcohol intake, and family history of pancreatic cancer. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). In the controls, we determined the associations of total and specific IgE measures with demographic characteristics, design factors, and risk factors, using χ2 tests to compare groups. For total IgE, results were log transformed to adjust for skewness in order to determine the geometric mean and SD and to assess the linear association of total IgE with risk. To identify potential confounding factors, we entered each of the demographic, design, and risk factors individually into the conditional logistic models and included those factors that changed the risk estimate by ≥5%. Confounders included in final models were cigarette smoking for total IgE and IgE to respiratory allergens and study center for IgE to food allergens.

We explored whether the risk of pancreatic cancer associated with serum IgE varied by age at baseline (<65 or ≥65), gender, smoking history (never smokers and former smokers who quit ≥15 years ago; current smokers and former smokers who quit <15 years ago), and BMI (dichotomized at the median value, 26.55). Stratum-specific ORs and 95% CIs were estimated from multivariable conditional logistic regression models with cross-product terms composed of the IgE measure and the potential effect modifier variable. To determine whether the association between IgE and risk varied by the length of time between randomization and diagnosis, we categorized cases and matched controls into groups of 0 to 5, 6 to 9, and 10 to 15 years between randomization and diagnosis and analyzed this association using conditional logistic regression with interaction terms.

All statistical analyses were performed in SAS version 9.2 (SAS Institute Inc.).

Characteristics of cases and controls are shown in Table 1. Slightly more than half the cases and controls were aged ≥65 years at baseline. Sixty-two percent were men, 90% were white, and 38% were college graduates. Cases were more likely to be current or recent cigarette smokers and more likely to report having diabetes.

Table 1.

Characteristics of cases and controls

Cases (N = 283)Controls (N = 544)
CharacteristicN (%)N (%)OR (95% CI)
Age (y), median (range) 65 (55–74) 65 (55–74)  
 <60 52 (18) 101 (19) NA 
 60–64 78 (28) 148 (27) NA 
 65–69 97 (34) 187 (34) NA 
 ≥70 56 (20) 108 (20) NA 
Gender 
 Female 108 (38) 206 (38) NA 
 Male 175 (62) 338 (62) NA 
Race 
 White, non-Hispanic 255 (90) 491 (90) NA 
 Black, non-Hispanic 9 (3) 18 (3) NA 
 Hispanic 4 (1) 7 (1) NA 
 Asian 14 (5) 26 (5) NA 
 Pacific Islander 1 (0) 2 (0) NA 
Education 
 High school or less 84 (30) 166 (31) 
 Post-high school and some college 91 (32) 175 (32) 1.00 (0.69–1.45) 
 College graduate 57 (20) 85 (16) 1.31 (0.84–2.05) 
 Post graduate 51 (18) 117 (22) 0.84 (0.54–1.30) 
Employment status 
 Working 85 (30) 184 (34) 
 Retired 156 (55) 282 (52) 1.32 (0.90–1.92) 
 Other (homemaker, disabled, unemployed) 42 (15) 76 (14) 1.26 (0.78–2.06) 
Marital status 
 Married or living as married 220 (78) 433 (80) 
 Not married 63 (22) 111 (20) 1.10 (0.77–1.56) 
Study center 
 University of Minnesota 75 (27) 122 (22) 
 University of Pittsburgh 42 (15) 57 (10) 1.17 (0.67–2.02) 
 Henry Ford Health System 31 (11) 62 (11) 0.73 (0.39–1.38) 
 University of Utah 27 (10) 61 (11) 0.65 (0.37–1.15) 
 Marshfield Clinic Research Foundation 25 (9) 70 (13) 0.53 (0.29–0.97) 
 Washington University in St. Louis 24 (8) 50 (9) 0.72 (0.39–1.32) 
 University of Colorado 20 (7) 47 (9) 0.62 (0.33–1.20) 
 Georgetown University 15 (5) 28 (5) 0.79 (0.38–1.65) 
 Pacific Health Research and Education Institute (Honolulu) 13 (5) 25 (5) 0.58 (0.09–3.73) 
 University of Alabama at Birmingham 11 (4) 22 (4) 0.74 (0.27–2.05) 
Season of blood draw 
 Spring/summer/fall (Mar–Oct) 202 (71) 397 (73) 
 Winter (Nov–Feb) 81 (29) 147 (27) 1.27 (0.71–2.28) 
Smoking 
 Never 106 (37) 272 (50) 
 Former quit ≥ 15 years ago 73 (26) 158 (29) 1.25 (0.86–1.81) 
 Former quit < 15 years ago 50 (18) 76 (14) 1.67 (1.08–2.57) 
 Current 54 (19) 38 (7) 3.88 (2.36–6.37) 
BMI (kg/m2
 <25 96 (34) 192 (35) 
 25–30 118 (42) 248 (46) 0.96 (0.68–1.35) 
 ≥30 67 (24) 102 (19) 1.34 (0.89–2.01) 
 Median (range) 26.6 (18.2–46.3) 26.6 (18.3–46.9)  
Diabetes 
 No 245 (87) 496 (91) 
 Yes 38 (13) 46 (8) 1.74 (1.09–2.8) 
Family history of pancreatic cancer 
 No 264 (94) 507 (94) 
 Yes or possibly 18 (6) 34 (6) 1.06 (0.58–1.91) 
Months until diagnosis of pancreatic cancer, median (range) 94.6 (3.6–181.5) NA  
Cases (N = 283)Controls (N = 544)
CharacteristicN (%)N (%)OR (95% CI)
Age (y), median (range) 65 (55–74) 65 (55–74)  
 <60 52 (18) 101 (19) NA 
 60–64 78 (28) 148 (27) NA 
 65–69 97 (34) 187 (34) NA 
 ≥70 56 (20) 108 (20) NA 
Gender 
 Female 108 (38) 206 (38) NA 
 Male 175 (62) 338 (62) NA 
Race 
 White, non-Hispanic 255 (90) 491 (90) NA 
 Black, non-Hispanic 9 (3) 18 (3) NA 
 Hispanic 4 (1) 7 (1) NA 
 Asian 14 (5) 26 (5) NA 
 Pacific Islander 1 (0) 2 (0) NA 
Education 
 High school or less 84 (30) 166 (31) 
 Post-high school and some college 91 (32) 175 (32) 1.00 (0.69–1.45) 
 College graduate 57 (20) 85 (16) 1.31 (0.84–2.05) 
 Post graduate 51 (18) 117 (22) 0.84 (0.54–1.30) 
Employment status 
 Working 85 (30) 184 (34) 
 Retired 156 (55) 282 (52) 1.32 (0.90–1.92) 
 Other (homemaker, disabled, unemployed) 42 (15) 76 (14) 1.26 (0.78–2.06) 
Marital status 
 Married or living as married 220 (78) 433 (80) 
 Not married 63 (22) 111 (20) 1.10 (0.77–1.56) 
Study center 
 University of Minnesota 75 (27) 122 (22) 
 University of Pittsburgh 42 (15) 57 (10) 1.17 (0.67–2.02) 
 Henry Ford Health System 31 (11) 62 (11) 0.73 (0.39–1.38) 
 University of Utah 27 (10) 61 (11) 0.65 (0.37–1.15) 
 Marshfield Clinic Research Foundation 25 (9) 70 (13) 0.53 (0.29–0.97) 
 Washington University in St. Louis 24 (8) 50 (9) 0.72 (0.39–1.32) 
 University of Colorado 20 (7) 47 (9) 0.62 (0.33–1.20) 
 Georgetown University 15 (5) 28 (5) 0.79 (0.38–1.65) 
 Pacific Health Research and Education Institute (Honolulu) 13 (5) 25 (5) 0.58 (0.09–3.73) 
 University of Alabama at Birmingham 11 (4) 22 (4) 0.74 (0.27–2.05) 
Season of blood draw 
 Spring/summer/fall (Mar–Oct) 202 (71) 397 (73) 
 Winter (Nov–Feb) 81 (29) 147 (27) 1.27 (0.71–2.28) 
Smoking 
 Never 106 (37) 272 (50) 
 Former quit ≥ 15 years ago 73 (26) 158 (29) 1.25 (0.86–1.81) 
 Former quit < 15 years ago 50 (18) 76 (14) 1.67 (1.08–2.57) 
 Current 54 (19) 38 (7) 3.88 (2.36–6.37) 
BMI (kg/m2
 <25 96 (34) 192 (35) 
 25–30 118 (42) 248 (46) 0.96 (0.68–1.35) 
 ≥30 67 (24) 102 (19) 1.34 (0.89–2.01) 
 Median (range) 26.6 (18.2–46.3) 26.6 (18.3–46.9)  
Diabetes 
 No 245 (87) 496 (91) 
 Yes 38 (13) 46 (8) 1.74 (1.09–2.8) 
Family history of pancreatic cancer 
 No 264 (94) 507 (94) 
 Yes or possibly 18 (6) 34 (6) 1.06 (0.58–1.91) 
Months until diagnosis of pancreatic cancer, median (range) 94.6 (3.6–181.5) NA  

NOTE: ORs estimated using conditional logistic regression. Columns may not add to total because of missing values.

Abbreviation: NA, not applicable.

For total IgE, the distribution of results in controls was as follows: normal, 41% (n = 224); borderline, 35% (n = 192); elevated, 23% (n = 126). Men were more likely than women to have borderline or elevated total IgE, as were current smokers and those who quit <15 years ago (data not shown in tables). Twenty-eight percent of controls (n = 150) had positive IgE to respiratory allergens. They were more likely to be men and non-white, more likely to be currently working, and less likely to report family history of pancreatic cancer. There was a higher percentage with positive results from the University of Colorado, Georgetown University, and Hawaii. Six percent of controls (n = 35) had positive results for IgE to foods. They were more likely to be younger (<65 years), women, and not married, although these results were not statistically significant.

There were no differences between cases and controls in the IgE measures (Table 2). For total IgE, the adjusted ORs were 0.84 (95% CI, 0.59–1.20) for borderline IgE and 1.22 (95% CI, 0.84–1.78) for elevated IgE, compared with normal levels. For a higher category of total IgE (>310 kU/L), risk was slightly higher (OR, 1.42; 95% CI, 0.85–2.37). There was no association with risk when total IgE was analyzed as a log-transformed continuous variable (OR, 1.04; 95% CI, 0.95–1.15, data not shown in tables). For positive results for IgE to respiratory allergens, the adjusted OR was 1.16 (95% CI, 0.84–1.61) and for food allergens, the adjusted OR was 1.57 (95% CI, 0.90–2.74).

Table 2.

Risk of pancreatic cancer associated with measures of IgE

Cases (N = 283)Controls (N = 544)
N (%)N (%)OR (95% CI)
Total IgE 
 Normal (<25 kU/L) 113 (40) 224 (41) 
 Borderline (25–100 kU/L) 87 (31) 192 (35) 0.84 (0.59–1.20) 
 Elevated (>100 kU/L) 81 (29) 126 (23) 1.22 (0.84–1.78) 
  >100–310 kU/L 45 (16) 79 (15) 1.09 (0.68–1.73) 
  >310 kU/L 36 (13) 47 (9) 1.42 (0.85–2.37) 
 Median (range) 32.7 (1–12662) 31.9 (1–4099)  
 Geometric mean (SD) 41.3 (5.26) 35.5 (4.66)  
IgE to respiratory allergens 
 Negative (<35 kU/L) 198 (70) 392 (72) 
 Positive (≥35 kU/L) 85 (30) 150 (28) 1.16 (0.84–1.61) 
IgE to food allergens 
 Negative (<35 kU/L) 257 (91) 506 (93) 
 Positive (≥35 kU/L) 26 (9) 35 (6) 1.57 (0.90–2.74) 
Cases (N = 283)Controls (N = 544)
N (%)N (%)OR (95% CI)
Total IgE 
 Normal (<25 kU/L) 113 (40) 224 (41) 
 Borderline (25–100 kU/L) 87 (31) 192 (35) 0.84 (0.59–1.20) 
 Elevated (>100 kU/L) 81 (29) 126 (23) 1.22 (0.84–1.78) 
  >100–310 kU/L 45 (16) 79 (15) 1.09 (0.68–1.73) 
  >310 kU/L 36 (13) 47 (9) 1.42 (0.85–2.37) 
 Median (range) 32.7 (1–12662) 31.9 (1–4099)  
 Geometric mean (SD) 41.3 (5.26) 35.5 (4.66)  
IgE to respiratory allergens 
 Negative (<35 kU/L) 198 (70) 392 (72) 
 Positive (≥35 kU/L) 85 (30) 150 (28) 1.16 (0.84–1.61) 
IgE to food allergens 
 Negative (<35 kU/L) 257 (91) 506 (93) 
 Positive (≥35 kU/L) 26 (9) 35 (6) 1.57 (0.90–2.74) 

NOTE: ORs estimated using conditional logistic regression adjusting for smoking (for total IgE and IgE to respiratory allergens; never, former quit >15 years ago, former quit <15 years ago, current) or study center (for IgE to food allergens).

Associations of the total and food IgE measures varied according to age (Table 3), with higher IgE related to increased risk in those ages ≥65 years, whereas in those <65 years, ORs were <1. For total IgE, OR = 1.43 (95% CI, 0.88–2.32) for borderline and OR = 1.98 (95% CI, 1.16–3.37) for elevated IgE in older respondents, in contrast to OR = 0.45 (95% CI, 0.26–0.77) for borderline and OR = 0.71 (95% CI, 0.41–1.24) for elevated IgE in younger respondents (Pinteraction 0.003). The patterns were consistent when we examined a higher category of total IgE (>310 kU/L; data not shown). IgE to food was positively associated with risk for older respondents (OR, 2.83; 95% CI, 1.29–6.20) but not for younger respondents (OR, 0.80; 95% CI, 0.34–1.91; Pinteraction 0.03). The pattern was similar for IgE to respiratory allergens but neither the ORs within strata nor the interaction was significant.

Table 3.

Interactions of IgE measures with age groups and length of time until case diagnosis

Age
<65≥65Pinteraction
Total IgE 
 Cases/controls 130/247 151/295   
 Normal  0.003 
 Borderline 0.45 (0.26–0.77) 1.43 (0.88–2.32)   
 Elevated 0.71 (0.41–1.24) 1.98 (1.16–3.37)   
IgE to respiratory allergens 
 Cases/controls 130/247 153/295   
 Negative  0.25 
 Positive 0.94 (0.58–1.53) 1.39 (0.89–2.18)   
IgE to food allergens 
 Cases/controls 130/247 153/294   
 Negative  0.03 
 Positive 0.80 (0.34–1.91) 2.83 (1.29–6.20)   
 Years between enrollment and diagnosis  
 0–5 y 6–9 y 10–15 y  
Total IgE 
 Cases/controls 98/188 105/200 78/154  
 Normal  
 Borderline 0.64 (0.35–1.17) 1.14 (0.64–2.01) 0.79 (0.40–1.55) 0.63 
 Elevated 1.26 (0.66–2.41) 1.45 (0.77–2.76) 0.96 (0.49–1.91)  
IgE to respiratory allergens 
 Cases/controls 98/188 107/200 78/154  
 Negative 0.36 
 Positive 1.37 (0.76–2.46) 1.35 (0.80–2.28) 0.80 (0.43–1.48)  
IgE to food allergens 
 Cases/controls 98/188 107/200 78/153  
 Negative 0.98 
 Positive 1.47 (0.53–4.07) 1.56 (0.64–3.81) 1.68 (0.63–4.48)  
Age
<65≥65Pinteraction
Total IgE 
 Cases/controls 130/247 151/295   
 Normal  0.003 
 Borderline 0.45 (0.26–0.77) 1.43 (0.88–2.32)   
 Elevated 0.71 (0.41–1.24) 1.98 (1.16–3.37)   
IgE to respiratory allergens 
 Cases/controls 130/247 153/295   
 Negative  0.25 
 Positive 0.94 (0.58–1.53) 1.39 (0.89–2.18)   
IgE to food allergens 
 Cases/controls 130/247 153/294   
 Negative  0.03 
 Positive 0.80 (0.34–1.91) 2.83 (1.29–6.20)   
 Years between enrollment and diagnosis  
 0–5 y 6–9 y 10–15 y  
Total IgE 
 Cases/controls 98/188 105/200 78/154  
 Normal  
 Borderline 0.64 (0.35–1.17) 1.14 (0.64–2.01) 0.79 (0.40–1.55) 0.63 
 Elevated 1.26 (0.66–2.41) 1.45 (0.77–2.76) 0.96 (0.49–1.91)  
IgE to respiratory allergens 
 Cases/controls 98/188 107/200 78/154  
 Negative 0.36 
 Positive 1.37 (0.76–2.46) 1.35 (0.80–2.28) 0.80 (0.43–1.48)  
IgE to food allergens 
 Cases/controls 98/188 107/200 78/153  
 Negative 0.98 
 Positive 1.47 (0.53–4.07) 1.56 (0.64–3.81) 1.68 (0.63–4.48)  

NOTE: Stratum-specific ORs estimated using conditional logistic regression models with interaction terms and adjusting for smoking (for total IgE and IgE to respiratory allergens; never, former quit >15 years ago, former quit <15 years ago, current) or study center (for IgE to food allergens).

For other stratified analyses, there were few differences between stratum-specific ORs and no statistically significant interactions (data not shown in tables). There was no pattern of association according to time between randomization and diagnosis for any of the IgE measures (Table 3). For IgE to respiratory allergens, there was a suggestion that positive results were inversely associated with risk in those with 10 to 15 years between randomization and diagnosis (OR, 0.80; 95% CI, 0.43–1.48). We investigated whether there was a difference between younger and older age groups in time from randomization to diagnosis, but results were very similar (mean 90.8 months in cases ages <65 and 88.7 months in cases ages ≥65 years).

In the sample as a whole, there were no statistically significant associations of the 3 measures of IgE with risk. Although there is a well-documented relationship between self-reported allergies and reduced risk of pancreatic cancer (2–5), the concordance between self-reported allergy and serum IgE measures is notably poor (8, 9): in data from the National Health and Nutrition Examination Survey (NHANES), only 52% of those who reported any allergy had positive results for IgE to 1 or more of 10 specific IgEs studied (9). Few studies of pancreatic cancer have included questions about food allergies and findings to date are inconsistent (4). It may be particularly difficult for people to distinguish between IgE-mediated sensitivity and other types of food intolerance.

The finding of differences in risk according to age was unexpected and was not related to time between enrollment and diagnosis. Older individuals generally have lower levels of IgE (10); whether the cases harbored higher IgE levels over the long term or whether some immune factor triggered this closer to the time of diagnosis cannot be determined. Our findings on differences in age groups could also be because of chance.

Only one study to date has reported on total IgE and IgE for airborne allergens in relation to risk of pancreatic cancer (11). This Swedish study linked records from patients at an immunology clinic to records from a cancer registry and concluded that there were no increased or decreased risks. This study is limited by the young age of the patients with allergies (65% <40 years) and the short average follow-up (<7 years). In glioma, another cancer for which self-reported allergies are also related to reduced risk, 3 prospective studies investigated serum IgE (12–14). Although some measures showed reduced risk with higher IgE, overall there were few significant findings and little consistency among studies.

The proportion of controls in this study with positive IgE measures was similar to those reported in other recent studies, for borderline and elevated total IgE (10, 15), IgE to panels of specific respiratory allergens (9, 15–17), and IgE to foods (8, 18). Total IgE (19–21) and IgE to respiratory allergens (20, 22) have been found to be stable over time in individuals for about 10 years, although less is known about the stability over time for food IgE in adults.

Strengths of this study include a sample size large enough to identify an inverse OR of ∼0.60 for borderline and elevated total IgE and for respiratory allergies, although there was less power for food allergies. Higher IgE levels are used clinically to identify food allergies (23, 24), but there were too few exposed to evaluate higher levels in our study. In addition, the longest time between cohort entry and diagnosis was 15 years, with a median follow-up of 7 years. Although pancreatic cancer often appears to develop and metastasize quickly, there is recent evidence that it develops, like other cancers, over a period of about 20 years (25).

In conclusion, the reported association of self-reported allergies with reduced risk of pancreatic cancer is not reflected in lower levels of IgE among cases, suggesting that this association operates through some mechanism other than a systemic immune response to allergens.

No potential conflicts of interest were disclosed.

Conception and design: S.H. Olson, R.C. Kurtz, R.Z. Stolzenberg-Solomon

Development of methodology: S.H. Olson, J.L. Wiemels, R.Z. Stolzenberg-Solomon, W.R. Reisacher

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.L. Wiemels, M. Zhou, R.Z. Stolzenberg-Solomon, J. Patoka

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S.H. Olson, J. Wang, M. Hsu

Writing, review, and/or revision of the manuscript: S.H. Olson, M. Hsu, J.L. Wiemels, W.R. Reisacher, J. Wang, D.T. Silverman, R.Z. Stolzenberg-Solomon, P.M. Bracci

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.L. Wiemels, R.C. Kurtz, J. Patoka

Study supervision: J.L. Wiemels, R.C. Kurtz

This project was supported by U01CA150138 to Dr. S.H. Olson.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
SEER Stat Fact Sheets: Pancreas
.
SEER Cancer Statistics
[cited 2014 02/17]. Available from
: http://seer.cancer.gov/statfacts/html/pancreas.html.
2.
Gandini
S
,
Lowenfels
AB
,
Jaffee
EM
,
Armstrong
TD
,
Maisonneuve
P
. 
Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms
.
Cancer Epidemiol Biomarkers Prev
2005
;
14
:
1908
16
.
3.
Olson
SH
. 
Selected medical conditions and risk of pancreatic cancer
.
Mol Carcinog
2012
;
51
:
75
97
.
4.
Olson
SH
,
Hsu
M
,
Satagopan
JM
,
Maisonneuve
P
,
Silverman
DT
,
Lucenteforte
E
, et al
Allergies and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer case-control consortium
.
Am J Epidemiol
2013
;
178
:
691
700
.
5.
Turner
MC
. 
Epidemiology: allergy history, IgE, and cancer
.
Cancer Immunol Immunother
2012
;
61
:
1493
510
.
6.
Prorok
PC
,
Andriole
GL
,
Bresalier
RS
,
Buys
SS
,
Chia
D
,
Crawford
ED
, et al
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
.
Control Clin Trials
2000
;
21
:
273S
309S
.
7.
Pharmacia Diagnostics
.
[cited 2013 09/05]. Available from
: http://www.phadia.com/en-GB/5/Products/ImmunoCAP-Assays/1/
8.
Gislason
D
,
Bjornsson
E
,
Gislason
T
,
Janson
C
,
Sjoberg
O
,
Elfman
L
, et al
Sensitization to airborne and food allergens in Reykjavik (Iceland) and Uppsala (Sweden)—a comparative study
.
Allergy
1999
;
54
:
1160
7
.
9.
Hoppin
JA
,
Jaramillo
R
,
Salo
P
,
Sandler
DP
,
London
SJ
,
Zeldin
DC
. 
Questionnaire predictors of atopy in a US population sample: findings from the National Health and Nutrition Examination Survey, 2005–2006
.
Am J Epidemiol
2011
;
173
:
544
52
.
10.
Tschopp
JM
,
Sistek
D
,
Schindler
C
,
Leuenberger
P
,
Perruchoud
AP
,
Wuthrich
B
, et al
Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults
.
Allergy
1998
;
53
:
608
13
.
11.
Lindelof
B
,
Granath
F
,
Tengvall-Linder
M
,
Ekbom
A
. 
Allergy and cancer
.
Allergy
2005
;
60
:
1116
20
.
12.
Calboli
FC
,
Cox
DG
,
Buring
JE
,
Gaziano
JM
,
Ma
J
,
Stampfer
M
, et al
Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies
.
J Natl Cancer Inst
2011
;
103
:
1588
95
.
13.
Schlehofer
B
,
Siegmund
B
,
Linseisen
J
,
Schuz
J
,
Rohrmann
S
,
Becker
S
, et al
Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort
.
Allergy
2011
;
66
:
1434
41
.
14.
Schwartzbaum
J
,
Ding
B
,
Johannesen
TB
,
Osnes
LT
,
Karavodin
L
,
Ahlbom
A
, et al
Association between prediagnostic IgE levels and risk of glioma
.
J Natl Cancer Inst
2012
;
104
:
1251
9
.
15.
Wiemels
JL
,
Wiencke
JK
,
Patoka
J
,
Moghadassi
M
,
Chew
T
,
McMillan
A
, et al
Reduced immunoglobulin E and allergy among adults with glioma compared with controls
.
Cancer Res
2004
;
64
:
8468
73
.
16.
Court
CS
,
Cook
DG
,
Strachan
DP
. 
The descriptive epidemiology of house dust mite-specific and total immunoglobin E in England using a nationally representative sample
.
Clin Exp Allergy
2002
;
32
:
1033
41
.
17.
Kerkhof
M
,
Dubois
AE
,
Postma
DS
,
Schouten
JP
,
de Monchy
JG
. 
Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults
.
Allergy
2003
;
58
:
905
11
.
18.
Keet
CA
,
Wood
RA
,
Matsui
EC
. 
Limitations of reliance on specific IgE for epidemiologic surveillance of food allergy
.
J Allergy Clin Immunol
2012
;
130
:
1207
9
e10
.
19.
Barbee
RA
,
Halonen
M
,
Kaltenborn
W
,
Lebowitz
M
,
Burrows
B
. 
A longitudinal study of serum IgE in a community cohort: correlations with age, sex, smoking, and atopic status
.
J Allergy Clin Immunol
1987
;
79
:
919
27
.
20.
Jarvis
D
,
Luczynska
C
,
Chinn
S
,
Potts
J
,
Sunyer
J
,
Janson
C
, et al
Change in prevalence of IgE sensitization and mean total IgE with age and cohort
.
J Allergy Clin Immunol
2005
;
116
:
675
82
.
21.
Oryszczyn
MP
,
Annesi
I
,
Neukirch
F
,
Dore
MF
,
Kauffmann
F
. 
Longitudinal observations of serum IgE and skin prick test response
.
Am J Respir Crit Care Med
1995
;
151
:
663
8
.
22.
Linneberg
A
,
Nielsen
NH
,
Madsen
F
,
Frolund
L
,
Dirksen
A
,
Jorgensen
T
. 
Is the increase in allergic respiratory disease caused by a cohort effect?
Clin Exp Allergy
2002
;
32
:
1702
5
.
23.
Liu
AH
,
Jaramillo
R
,
Sicherer
SH
,
Wood
RA
,
Bock
SA
,
Burks
AW
, et al
National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005–2006
.
J Allergy Clin Immunol
2010
;
126
:
798
806
e13
.
24.
Sampson
HA
. 
Update on food allergy
.
J Allergy Clin Immunol
2004
;
113
:
805
19
;
quiz 20
.
25.
Yachida
S
,
Jones
S
,
Bozic
I
,
Antal
T
,
Leary
R
,
Fu
B
, et al
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
.
Nature
2010
;
467
:
1114
7
.